The Food and Drug Administration is taking steps to prevent brand name drugmakers from organizing citizen petitions aimed at delaying approval of generic competition, which the agency says is unnecessarily bogging it down with meritless petitions.

FDA Commissioner Scott Gottlieb announced new regulatory guidance on Tuesday as part of a broader effort to crack down on practices that officials say brand name drugmakers use to stifle competition.

Recommended Stories

FDA approves first generic competitor for EpiPen

Cut pharmaceutical costs with a tried-and-true approach: the free market

FDA takes bigger role in lowering drug prices